Abstracts tagged "osteoarthritis and regeneration"

Abstract Number: 848 • 2018 ACR/ARHP Annual Meeting
A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration
Carmen Corciulo¹, Cristina Castro², Samson Jacob³, David Fenyo³, Oran Kennedy⁴ and Bruce N. Cronstein⁵, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, NYU School of Medicine, New York, NY, ³Institute for Systems Genetics, NYU School of Medicine, New York, NY, ⁴Department of Anatomy, Royal College of Surgeons, Dublin, Ireland, ⁵Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: We previously found that intra-articular injections of liposomal preparations of adenosine completely prevent progression and reverse cartilage loss in post-traumatic OA. TGF-β signaling plays…
Abstract Number: 312 • 2015 ACR/ARHP Annual Meeting
Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Yusuf Yazici¹, Timothy E. McAlindon², Roy Fleischmann³, Allan Gibofsky⁴, Nancy E. Lane⁵, Alan J. Kivitz⁶, Nebojsa Skrepnik⁷, Eddie Armas⁸, Christopher J. Swearingen¹, Anita DiFrancesco¹, Jeyanesh R. S. Tambiah¹, John Hood¹ and Marc C. Hochberg⁹, ¹Samumed, San Diego, CA, ²Tufts Medical Center, Boston, MA, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ⁵UC Davis Medical Center, Sacramento, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Tucson Orthopaedic Institute, Tucson, AZ, ⁸Well Pharma Medical Research, Miami, FL, ⁹University of Maryland School of Medicine, Baltimore, MD, USA, Baltimore, MD
Background/Purpose: Knee osteoarthritis (OA) is characterized by the destruction of articular cartilage, subchrondral bone alterations and varying degrees of synovitis. Current OA treatments are limited…
Abstract Number: 313 • 2015 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Yusuf Yazici¹, Sharmila Majumdar², Timothy E. McAlindon³, Roy Fleischmann⁴, Allan Gibofsky⁵, Marc C. Hochberg⁶, Christopher J. Swearingen¹, Anita DiFrancesco¹, Jeyanesh R. S. Tambiah¹, John Hood¹ and Nancy E. Lane⁷, ¹Samumed, San Diego, CA, ²Radiology, UCSF School of Medicine, San Francisco, CA, ³Rheumatology, Tufts Medical Center, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, University of Maryland, Baltimore, MD, ⁷Center for Musculoskeletal Health, Univ of California at Davis, Sacramento, CA
Background/Purpose: Knee osteoarthritis (OA) is characterized by the destruction of articular cartilage, subchrondral bone alterations and varying degrees of synovitis. Current OA treatments are limited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].